Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma

Author:

Ryu Kum Hei,Park Sunhwa,Chun Jung Won,Cho Eunhae,Choi Jongmun,Lee Dong-Eun,Shim Hyoeun,Kim Yun-Hee,Han Sung-Sik,Park Sang-Jae,Woo Sang Myung,Kong Sun-Young

Abstract

Purpose The genetic attribution for pancreatic ductal adenocarcinoma (PDAC) has been reported as 5%-10%. However, the incidence of germline pathogenic variants (PVs) in Korean PDAC patients has not been thoroughly investigated. Therefore, we studied to identify the risk factors and prevalence of PV for future treatment strategies in PDAC.Materials and Methods Total of 300 (155 male) patients with a median age of 65 years (range, 33 to 90 years) were enrolled in National Cancer Center in Korea. Cancer predisposition genes, clinicopathologic characteristics, and family history of cancer were analyzed.Results PVs were detected in 20 patients (6.7%, median age 65) in <i>ATM</i> (n=7, 31.8%), <i>BRCA1</i> (n=3, 13.6%), <i>BRCA2</i> (n=3), and <i>RAD51D</i> (n=3). Each one patient showed <i>TP53, PALB2, PMS2, RAD50, MSH3,</i> and <i>SPINK1</i> PV. Among them, two likely PVs were in <i>ATM</i> and <i>RAD51D</i>, respectively. Family history of various types of cancer including pancreatic cancer (n=4) were found in 12 patients. Three patients with <i>ATM</i> PVs and a patient with three germline PVs (<i>BRCA2, MSH3,</i> and <i>RAD51D</i>) had first-degree relatives with pancreatic cancer. Familial pancreatic cancer history and PVs detection had a significant association (4/20, 20% vs. 16/264, 5.7%; p=0.035).Conclusion Our study demonstrated that germline PVs in <i>ATM, BRCA1, BRCA2,</i> and <i>RAD51D</i> are most frequent in Korean PDAC patients and it is comparable to those of different ethnic groups. Although this study did not show guidelines for germline predisposition gene testing in patients with PDAC in Korea, it would be emphasized the need for germline testing for all PDAC patients.

Funder

National Cancer Center

Publisher

Korean Cancer Association

Subject

Cancer Research,Oncology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3